Document is current
Any future updates will be listed below
-
Authors
Schmitz, Robin https://orcid.org/0000-0003-1286-0457
Fitch, Zachary W. https://orcid.org/0000-0002-1395-1513
Schroder, Paul M.
Choi, Ashley Y. https://orcid.org/0000-0001-6624-6378
Manook, Miriam https://orcid.org/0000-0002-6474-6122
Yoon, Janghoon https://orcid.org/0000-0001-8543-194X
Song, Mingqing https://orcid.org/0000-0002-2462-9351
Yi, John S. https://orcid.org/0000-0001-7777-2437
Khandelwal, Sanjay https://orcid.org/0000-0002-5661-3856
Arepally, Gowthami M.
Farris, Alton B. https://orcid.org/0000-0001-5534-7763
Reis, Edimara S.
Lambris, John D.
Kwun, Jean https://orcid.org/0000-0002-8563-5472
Knechtle, Stuart J. https://orcid.org/0000-0002-1625-385X
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (U19AI131471)
- License Information
-
More Information
Article History
Received: 19 October 2020
Accepted: 24 August 2021
First Online: 15 September 2021
Competing interests
: J.D.L. is the founder of Amyndas Pharmaceuticals, which is developing complement inhibitors for therapeutic purposes and inventor of patents or patent applications that describe the use of complement inhibitors for therapeutic purposes, some of which are developed by Amyndas Pharmaceuticals. J.D.L. is also the inventor of the compstatin technology licensed to Apellis Pharmaceuticals (i.e., 4(1MeW)7 W/POT-4/APL-1 and PEGylated derivatives such as APL-2/Pegcetacoplan). The other authors declare no competing interest.
